Vol 13, No 1 (2017)
Review paper
Published online: 2017-07-21
Page views 454
Article views/downloads 1196
Get Citation

Connect on Social Media

Connect on Social Media

Olaratumab (LARTRUVO®) as a new therapeutic option in the treatment of patients with advanced soft tissue sarcomas

Paweł Rogala1, Piotr Rutkowski1
DOI: 10.5603/OCP.2017.0001
Oncol Clin Pract 2017;13(1):1-7.

Abstract

Olaratumab is a newly approved human monoclonal IgG1 antibody against platelet-derived growth factor alpha (PDGFR-α). In a relatively small, randomised phase 2 trial the drug given in combination with doxorubicin produced an overall survival improvement in patients with unresectable and/or metastatic soft tissue sarcomas. Further studies are necessary to establish the role of this agent in the treatment of advanced sarcomas. In this paper the current clinical data on olaratumab are presented.

References

  1. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm526087.htm.
  2. Kohler N, Lipton A. Platelets as a source of fibroblast growth-promoting activity. Exp Cell Res. 1974; 87(2): 297–301.
  3. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008; 22(10): 1276–1312.
  4. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004; 15(4): 275–286.
  5. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013; 382(9896): 973–983.
  6. Loizos N, Xu Y, Huber J, et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther. 2005; 4(3): 369–379.
  7. Russell MR, Liu Q, Fatatis A. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Cancer Res. 2010; 16(20): 5002–5010.
  8. Gerber DE, Gupta P, Dellinger MT, et al. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts. Mol Cancer Ther. 2012; 11(11): 2473–2482.
  9. Heinrich M, Rankin C, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7): 472–480.
  10. Jayson GC, Parker GJM, Mullamitha S, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol. 2005; 23(5): 973–981.
  11. Druker B, Talpaz M, Resta D, et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. N Eng J Med. 2001; 344(14): 1031–1037.
  12. https://ec.europa.eu/health/documents/community-register/2016/20161109136289/anx_136289_pl.pdf.
  13. Chiorean E.G., Sweeney C., Youssoufian H. i wsp. Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFRα) in patients with advanced solid malignancies [abstract 511 and poster]. Presented at EORTC-NCI-AACR Annual Meeting 2008 Geneva, Switzerland, Oct 21–24 2008.
  14. Chiorean EG, Sweeney C, Youssoufian H, et al. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014; 73(3): 595–604.
  15. Scher HI. Prostate Cancer Clinical Trial End Points: “RECIST”ing a step backwards. Clin Cancer Res. 2005; 11(14): 5223–5232.
  16. Fudge K, Bostwick DG, Stearns ME. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate. 1996; 29(5): 282–286, doi: 10.1002/(SICI)1097-0045(199611)29:5<282::AID-PROS2>3.0.CO;2-C.
  17. Knösel T, Chen Y, Altendorf-Hofmann A, et al. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event. J Cancer Res Clin Oncol. 2012; 138(3): 397–403.
  18. Doi T, Ma Y, Dontabhaktuni A, et al. Phase I study of olaratumab in Japanese patients with advanced solid tumors. Cancer Sci. 2014; 105(7): 862–869.
  19. Wagner AJ, Kindler H, Gelderblom H, et al. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Annals of Oncology. 2017; 28(3): 541–546.
  20. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016; 388(10043): 488–497.
  21. Tonra J, Deevi D, Carrick F, et al. Enhanced antitumour activity of anti-platelet derived growth factor receptor alpha antibody, IMC-3G3, in combination with doxorubicin against a human soft-tissue sarcoma xenograft model. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference; Philadelphia, PA, USA 2005 Nov 14–18. : A67.
  22. Graaf Wv, Blay JY, Chawla S, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2012; 379(9829): 1879–1886.
  23. Demetri G, Mehren Mv, Jones R, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016; 34(8): 786–793.
  24. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016; 387(10028): 1629–1637.